Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H2 2019
Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H2 2019
SUMMARY
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) is a member of MAP kinase kinase kinase family encoded by MAP3K5 gene. It plays an important role in the cascades of cellular responses evoked by changes in the environment. It mediates signaling for determination of cell fate such as differentiation and survival. It plays a crucial role in the apoptosis signal transduction pathway through mitochondria-dependent caspase activation. It is essential for host defense against a wide range of pathogens. It mediates signal transduction of various stressors like oxidative stress as well as by receptor-mediated inflammatory signals.
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 9 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Cardiovascular, Central Nervous System, Immunology, Metabolic Disorders, Toxicology, Genito Urinary System And Sex Hormones, Hematological Disorders, Musculoskeletal Disorders, Oncology and Undisclosed which include indications Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Drug Toxicity, Hepatic Injury, Inflammation, Myocardial Infarction, Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Acute Renal Failure (ARF) (Acute Kidney Injury), Alcoholic Hepatitis, Amyotrophic Lateral Sclerosis, Cardiovascular Disease, Fibrosis, Gastric Cancer, Hepatic Encephalopathy, Pain, Pulmonary Hypertension, Rheumatoid Arthritis, Thrombosis and Unspecified.
The latest report Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H2 2019, outlays comprehensive information on the Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) is a member of MAP kinase kinase kinase family encoded by MAP3K5 gene. It plays an important role in the cascades of cellular responses evoked by changes in the environment. It mediates signaling for determination of cell fate such as differentiation and survival. It plays a crucial role in the apoptosis signal transduction pathway through mitochondria-dependent caspase activation. It is essential for host defense against a wide range of pathogens. It mediates signal transduction of various stressors like oxidative stress as well as by receptor-mediated inflammatory signals.
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 9 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Cardiovascular, Central Nervous System, Immunology, Metabolic Disorders, Toxicology, Genito Urinary System And Sex Hormones, Hematological Disorders, Musculoskeletal Disorders, Oncology and Undisclosed which include indications Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Drug Toxicity, Hepatic Injury, Inflammation, Myocardial Infarction, Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Acute Renal Failure (ARF) (Acute Kidney Injury), Alcoholic Hepatitis, Amyotrophic Lateral Sclerosis, Cardiovascular Disease, Fibrosis, Gastric Cancer, Hepatic Encephalopathy, Pain, Pulmonary Hypertension, Rheumatoid Arthritis, Thrombosis and Unspecified.
The latest report Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H2 2019, outlays comprehensive information on the Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25)
- The report reviews Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Overview
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Companies Involved in Therapeutics Development
Angion Biomedica Corp
Calchan Ltd
Chipscreen Biosciences Ltd
Enanta Pharmaceuticals Inc
FronThera US Pharmaceuticals LLC
Gilead Sciences Inc
Kyowa Kirin Co Ltd
Seal Rock Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Terns Pharmaceuticals Inc
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Drug Profiles
ANG-4102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-026856 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-027315 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-444217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-459679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selonsertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ASK1 for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ASK1 for Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fibrosis, Hematological Diseases and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ASK1 for Amyotropic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ASK1 for Myocardial Infarction, Neurodegenerative Diseases and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Dormant Products
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Discontinued Products
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2019: PathAI and Gilead show AI-powered pathology research models accurately interpret liver histology in patients with NASH at AASLD 2019
Apr 26, 2019: Gilead’s selonsertib fails in second Phase III trial for NASH
Apr 11, 2019: Enanta Pharmaceuticals to present preclinical data for Non-Alcoholic Steatohepatitis program EP-026856 at ILC 2019
Apr 11, 2019: Enanta Pharmaceuticals to present preclinical data for Non-Alcoholic Steatohepatitis program EP-027315 at ILC 2019
Feb 13, 2019: Gilead’s selonsertib fails in Phase III STELLAR-4 study for NASH
Nov 09, 2018: Seal Rock Therapeutics advancing differentiated ASK1 inhibitor lead candidate SRT-015 in nonalcoholic steatohepatitis (NASH)
Nov 09, 2018: Gilead Sciences presents data on Selonsertib at The Liver Meeting 2018
Oct 11, 2018: Gilead to present data on Selonsertib at The Liver Meeting 2018
Apr 13, 2018: Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress 2018
Apr 20, 2017: Gilead to Present Additional Clinical Data on Selonsertib at The International Liver Congress 2017
Nov 14, 2016: Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis Presented at The Liver Meeting 2016
Oct 20, 2016: Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis, Pulmonary Arterial Hypertension and Diabetic Kidney Disease
Apr 16, 2016: Gilead Presents New Data on GS-4997 at The International Liver Congress 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Overview
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Companies Involved in Therapeutics Development
Angion Biomedica Corp
Calchan Ltd
Chipscreen Biosciences Ltd
Enanta Pharmaceuticals Inc
FronThera US Pharmaceuticals LLC
Gilead Sciences Inc
Kyowa Kirin Co Ltd
Seal Rock Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Terns Pharmaceuticals Inc
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Drug Profiles
ANG-4102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-026856 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-027315 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-444217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-459679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selonsertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ASK1 for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ASK1 for Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fibrosis, Hematological Diseases and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ASK1 for Amyotropic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ASK1 for Myocardial Infarction, Neurodegenerative Diseases and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Dormant Products
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Discontinued Products
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2019: PathAI and Gilead show AI-powered pathology research models accurately interpret liver histology in patients with NASH at AASLD 2019
Apr 26, 2019: Gilead’s selonsertib fails in second Phase III trial for NASH
Apr 11, 2019: Enanta Pharmaceuticals to present preclinical data for Non-Alcoholic Steatohepatitis program EP-026856 at ILC 2019
Apr 11, 2019: Enanta Pharmaceuticals to present preclinical data for Non-Alcoholic Steatohepatitis program EP-027315 at ILC 2019
Feb 13, 2019: Gilead’s selonsertib fails in Phase III STELLAR-4 study for NASH
Nov 09, 2018: Seal Rock Therapeutics advancing differentiated ASK1 inhibitor lead candidate SRT-015 in nonalcoholic steatohepatitis (NASH)
Nov 09, 2018: Gilead Sciences presents data on Selonsertib at The Liver Meeting 2018
Oct 11, 2018: Gilead to present data on Selonsertib at The Liver Meeting 2018
Apr 13, 2018: Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress 2018
Apr 20, 2017: Gilead to Present Additional Clinical Data on Selonsertib at The International Liver Congress 2017
Nov 14, 2016: Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis Presented at The Liver Meeting 2016
Oct 20, 2016: Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis, Pulmonary Arterial Hypertension and Diabetic Kidney Disease
Apr 16, 2016: Gilead Presents New Data on GS-4997 at The International Liver Congress 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Angion Biomedica Corp, H2 2019
Pipeline by Calchan Ltd, H2 2019
Pipeline by Chipscreen Biosciences Ltd, H2 2019
Pipeline by Enanta Pharmaceuticals Inc, H2 2019
Pipeline by FronThera US Pharmaceuticals LLC, H2 2019
Pipeline by Gilead Sciences Inc, H2 2019
Pipeline by Kyowa Kirin Co Ltd, H2 2019
Pipeline by Seal Rock Therapeutics Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Terns Pharmaceuticals Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Angion Biomedica Corp, H2 2019
Pipeline by Calchan Ltd, H2 2019
Pipeline by Chipscreen Biosciences Ltd, H2 2019
Pipeline by Enanta Pharmaceuticals Inc, H2 2019
Pipeline by FronThera US Pharmaceuticals LLC, H2 2019
Pipeline by Gilead Sciences Inc, H2 2019
Pipeline by Kyowa Kirin Co Ltd, H2 2019
Pipeline by Seal Rock Therapeutics Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Terns Pharmaceuticals Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Angion Biomedica Corp
Calchan Ltd
Chipscreen Biosciences Ltd
Enanta Pharmaceuticals Inc
FronThera US Pharmaceuticals LLC
Gilead Sciences Inc
Kyowa Kirin Co Ltd
Seal Rock Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Terns Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Angion Biomedica Corp
Calchan Ltd
Chipscreen Biosciences Ltd
Enanta Pharmaceuticals Inc
FronThera US Pharmaceuticals LLC
Gilead Sciences Inc
Kyowa Kirin Co Ltd
Seal Rock Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Terns Pharmaceuticals Inc
